Maternal Opioid Use Disorder, Opioid Exposed Infant
Conditions
Keywords
maternal opioid use, neonatal abstinence syndrome, buprenorphine-naloxone
Brief summary
The purpose of this mechanistic study is to evaluate the effects that maternal buprenorphine-naloxone maintenance have on the neurobehavioral development of the fetus and infant. To accomplish this, the investigators will study a sample of 120 opioid dependent pregnant women that will receive buprenorphine-naloxone as part of substance abuse treatment at a comprehensive care treatment facility for pregnant and parenting women with substance use disorders. Fetal neurobehavior and maternal physiology will be assessed, via an established maternal-fetal data acquisition system, at 4 points during gestation: 24, 28, 32 and 36 weeks. Infant birth parameters and Neonatal Abstinence Syndrome (NAS) spectrum display will be evaluated at birth, and infant neurodevelopment will be assessed during the first month of life.
Detailed description
The project population will be 40 pregnant women with opioid use disorder inducted as outpatients to buprenorphine-naloxone maintenance. Subject treatment data, including medical and obstetric histories, drug use histories, demographic information and psychosocial information will be extracted from patient charts. Weekly urine toxicology testing will provide information regarding other substance use/misuse during the time of study participation. Study participants will undergo 2 60 minute maternal and fetal neurophysiologic monitoring sessions on one day at 4 points during gestation: 24, 28, 32 and 36 weeks, at times of trough (just before sublingual buprenorphine-naloxone or methadone daily dose) and peak (2 1/2 hours after dosing) maternal drug levels. Fetal cardiac (heart rate, heart rate variability, heart rate accelerations) and movement (total fetal movement, number and duration of movement bouts) and the correlation between the two (fetal heart rate-movement coupling) will be determined. Maternal physiologic measures will include heart period and variability, vagal tone, skin conductance and respiratory data. All maternal and fetal measures, with the exception of blood pressure, will be computed in 1-minute intervals and averaged over the 60 min recording. Infant birth data and birth parameters, and neonatal abstinence syndrome scores will be extracted from patient charts. Infants will undergo neurobehavioral testing using the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale, a 30 minute harmless assessment of infant functioning, on days 3, 14 and 30 of life.
Interventions
DEVICEfetal monitoring
Maternal fetal monitoring
Treatment for opioid use disorder
Sponsors
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
A group of n=40 study participants will receive buprenorphine-naloxone medication assisted therapy for the treatment of opioid use disorder during pregnancy. This group will undergo fetal monitoring at 24, 28, 32 and 36 weeks of gestation.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
No
Inclusion criteria
* Current opioid use disorder (OUD) as defined by DSM V criteria * singleton pregnancies, generally uncomplicated by conditions that jeopardize pregnancy outcome * Gestation less than 24 weeks
Exclusion criteria
* Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery; * Evidence of fetal malformation detected by prenatal ultrasound; * Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension; * Significant maternal psychopathology that would preclude informed consent; * Alcohol use disorder per DSM V criteria (see ascertainment methods below) * Women stable on methadone maintenance (defined as more than 3 consecutive days of dosing) * Women coming to treatment reporting street methadone use (for more than 3 consecutive days * Women not planning to receive obstetric care at the Center for Addiction and Pregnancy; - Women not planning to deliver their infants at Johns Hopkins Bayview Medical center * Women planning for adoption of their infant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fetal Heart Rate at 24 Weeks | 24 weeks of gestation | Fetal heart rate in beats per minute, mean over 60 minutes gestation. Fetal heart rate in msec at 24 weeks of gestation at times of peak maternal plasma drug concentrations |
| Fetal Heart Rate at 28 Weeks Gestation | 28 weeks of gestation | Fetal heart rate in beats per minute, mean over 60 minutes gestation. Fetal heart rate at 28 weeks of gestation at times of tpeak maternal plasma drug concentrations. |
| Fetal Heart Rate at 32 Weeks Gestation | 32 weeks of gestation | Fetal heart rate in beats per minute, mean over 60 minutes. Fetal heart rate at 32 weeks of gestation at times of peak maternal plasma drug concentrations |
| Fetal Heart Rate at 36 Weeks Gestation | 36 weeks of gestation | Fetal heart rate in beats per minute, mean over 60 minutes. Fetal heart rate at 36 weeks of gestation at times of peak maternal plasma drug concentrations. |
| Total Fetal Movement at 24 Weeks Gestation | 24 weeks of gestation | Total fetal movement at 24 weeks of gestation. Total number of fetal moves over 60 minutes via fetal monitoring at time of peak maternal plasma drug concentrations at 24 weeks of gestation. |
| Total Fetal Movement at 36 Weeks Gestation | 36 weeks of gestation | Total fetal movement over 60 minutes via fetal monitoring at 36 weeks of gestation. Nimber of fetal movements over 60 minutes via fetal monitoring at times of peak maternal plasma drug concentrations at 36 weeks of gestation. |
| Total Fetal Movement at 28 Weeks Gestation | 28 weeks of gestation | Total fetal movement over 60 minutes via fetal monitoring. Total fetal movement over 60 minutes via fetal monitoring at times of trough and peak maternal plasma drug concentrations at 28 weeks of gestation. |
| Total Fetal Movement at 32 Weeks Gestation | 32 weeks of gestation | Total fetal movement over 60 minutes via fetal monitoring at 32 weeks of gestation. Number of fetal moves over 60 minutes via fetal monitoring at times of peak maternal plasma drug concentrations at 32 weeks of gestation. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Buprenorphine-naloxone Treated Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
fetal monitoring: Maternal fetal monitoring
Buprenorphine Naloxone: Treatment for opioid use disorder | 26 |
| Total | 26 |
Baseline characteristics
| Characteristic | Buprenorphine-naloxone Treated |
|---|---|
| Age, Continuous | 29.6 years STANDARD_DEVIATION 4.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 9 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 17 Participants |
| Region of Enrollment United States | 26 Participants |
| Sex: Female, Male Female | 26 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 26 |
| other Total, other adverse events | 0 / 26 |
| serious Total, serious adverse events | 3 / 26 |
Outcome results
Primary
Fetal Heart Rate at 24 Weeks
Fetal heart rate in beats per minute, mean over 60 minutes gestation. Fetal heart rate in msec at 24 weeks of gestation at times of peak maternal plasma drug concentrations
Time frame: 24 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Fetal Heart Rate at 24 Weeks | 143.64 beats per minute | Standard Deviation 4.38 |
Primary
Fetal Heart Rate at 28 Weeks Gestation
Fetal heart rate in beats per minute, mean over 60 minutes gestation. Fetal heart rate at 28 weeks of gestation at times of tpeak maternal plasma drug concentrations.
Time frame: 28 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Fetal Heart Rate at 28 Weeks Gestation | 139.14 beats per minute | Standard Deviation 3.93 |
Primary
Fetal Heart Rate at 32 Weeks Gestation
Fetal heart rate in beats per minute, mean over 60 minutes. Fetal heart rate at 32 weeks of gestation at times of peak maternal plasma drug concentrations
Time frame: 32 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Fetal Heart Rate at 32 Weeks Gestation | 135.82 beats per minute | Standard Deviation 146.83 |
Primary
Fetal Heart Rate at 36 Weeks Gestation
Fetal heart rate in beats per minute, mean over 60 minutes. Fetal heart rate at 36 weeks of gestation at times of peak maternal plasma drug concentrations.
Time frame: 36 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Fetal Heart Rate at 36 Weeks Gestation | 131.99 beats per minute | Standard Deviation 5.52 |
Primary
Total Fetal Movement at 24 Weeks Gestation
Total fetal movement at 24 weeks of gestation. Total number of fetal moves over 60 minutes via fetal monitoring at time of peak maternal plasma drug concentrations at 24 weeks of gestation.
Time frame: 24 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Total Fetal Movement at 24 Weeks Gestation | 71.91 fetal movements | Standard Deviation 13.8 |
Primary
Total Fetal Movement at 28 Weeks Gestation
Total fetal movement over 60 minutes via fetal monitoring. Total fetal movement over 60 minutes via fetal monitoring at times of trough and peak maternal plasma drug concentrations at 28 weeks of gestation.
Time frame: 28 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Total Fetal Movement at 28 Weeks Gestation | 70.06 fetal movements | Standard Deviation 12.13 |
Primary
Total Fetal Movement at 32 Weeks Gestation
Total fetal movement over 60 minutes via fetal monitoring at 32 weeks of gestation. Number of fetal moves over 60 minutes via fetal monitoring at times of peak maternal plasma drug concentrations at 32 weeks of gestation.
Time frame: 32 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Total Fetal Movement at 32 Weeks Gestation | 66.00 fetal movements | Standard Deviation 19.13 |
Primary
Total Fetal Movement at 36 Weeks Gestation
Total fetal movement over 60 minutes via fetal monitoring at 36 weeks of gestation. Nimber of fetal movements over 60 minutes via fetal monitoring at times of peak maternal plasma drug concentrations at 36 weeks of gestation.
Time frame: 36 weeks of gestation
Population: Fetal monitoring performed for all participants enrolled in the study at that gestational age who met criteria for monitoring
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Buprenorphine-naloxone Treated | Total Fetal Movement at 36 Weeks Gestation | 59.07 fetal movements | Standard Deviation 17.17 |